Health Canada has issued updated guidance outlining the information required for the authorization of biosimilar biologic drugs, providing manufacturers with a clearer framework for demonstrating similarity to reference products.
The revised guidance, which reflects ongoing efforts to modernize regulatory oversight and align with international scientific standards, details the evidentiary expectations